KRAS Companion Test for Erbitux Wins OK
(MedPage Today) — A rapid molecular test for KRAS mutations has received FDA approval as an aid in identifying colorectal cancer patients who would benefit from cetuximab (Erbitux) treatment.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com